

GENE	POSITION	cDNA change	Aa change	rs ID	MAF cases-ctrls	ExAC	MA	SIFT	POLYPHEN	AA/Aa/aa cases	AA/Aa/aa ctrls	P-VALUE	OR
ABCA7	19:1043103	c.G643A	p.G215S	rs72973581	0.04669-0.07249	0.04316	A	tolerated	benign	0/31/301	1/96/579	0.02665	0.615
ABCA7	19:1050996	c.G2629A	p.A877T	rs74176364	0.003012-0.01183	0.01692	A	deleterious	benign	0/2/330	0/16/660	0.07264	0.25
ABCA7	19:1059056	c.G5435A	p.R1812H	rs114782266	0.01506-0.008136	0.01057	A	tolerated	benign	0/10/322	0/11/665	0.1625	1.87
ABCA7	19:1057343	c.G4795A	p.V1599M	rs117187003	0.006024-0.002219	0.003085	A	deleterious	probably damaging	0/4/328	0/3/673	0.2269	2.73
ABCA7	19:1047537	c.A2153C	p.N718T	rs3752239	0.01657-0.02448	0.07028	C	Deleterious	benign	0/11/321	0/33/641	0.3251	0.665
ABCA7	19:1043794	c.G1001A	p.R334Q	rs147846250	0.001506-0	0.0001995	A	Tolerated	benign	0/1/331	0/0/676	0.329	Inf
ABCA7	19:1044619	c.C1091G	p.P364R	rs146982710	0.001506-0	0.0003843	G	Tolerated	Possibly damaging	0/1/331	0/0/676	0.329	Inf
ABCA7	19:1046239	c.C1456G	p.P486A	rs141428162	0.001506-0	0.0003212	G	deleterious	Possibly damaging	0/1/331	0/0/676	0.3294	Inf
ABCA7	19:1047372	c.G2062A	p.A688T	rs376686030	0.001506-0		A	tolerated	Possibly damaging	0/1/331	0/0/676	0.3294	Inf
ABCA7	19:1053521	c.C3414G	p.S1138R	rs1053521	0.001506-0	0.00002865	G			0/1/331	0/0/676	0.3294	Inf
ABCA7	19:1056372	c.T4460G	p.V1487G	rs200825702	0.001506-0	0.0001245	G	deleterious	probably damaging	0/1/331	0/0/676	0.3294	inf
ABCA7	19:1056941	c.G4622A	p.C1541Y	rs145632609	0.001506-0	0.00004131	A	deleterious	probably damaging	0/1/331	0/0/676	0.3294	Inf
ABCA7	19:1056958	c.T4639C	p.S1547P		0.001506-0	0.00000826	C			0/1/331	0/0/676	0.3294	Inf
ABCA7	19:1057366	c.G4818T	p.Q1606H	NOVEL	0.001506-0		T			0/1/331	0/0/676	0.3294	Inf
ABCA7	19:1058655	c.G5188A	p.V1730I	NOVEL	0.001506-0		A			0/1/331	0/0/676	0.3294	inf
ABCA7	19:1044712	c.A1184G	p.H395R	rs3764647	0.0256-0.03333	0.06298	G	Tolerated	benign	0/17/315	0/45/630	0.4032	0.755
ABCA7	19:1043748	c.A955G	p.T319A	rs3752232	0.0256-0.03264	0.06039	G	Tolerated	benign	0/17/315	0/44/630	0.4035	0.77
ABCA7	19:1058176	c.A5057G	p.Q1686R	rs4147918	0.0256-0.0318	0.04785	G	Tolerated	benign	0/17/315	0/43/633	0.4812	0.794
ABCA7	19:1056109	c.C4283T	p.S1428L	rs145232000	0.001506-0.0007396	0.0001994	T	Tolerated	benign	0/1/331	0/1/675	0.5505	2.037
ABCA7	19:1053382	c.T3275G	p.V1092G	rs201213180	0.00303-0.0007452	0.0008056	G	deleterious	Possibly damaging	1/0/329	0/1/670	0.5509	2.034
ABCA7	19:1041922	c.C253A	p.L85M	rs146597357	0-0.0007396	0.0002568	A	Deleterious	benign	0/0/332	0/1/675	1	0
ABCA7	19:1041950	c.T281C	p.L94P	NOVEL	0-0.0007396		C			0/0/332	0/1/675	1	0
ABCA7	19:1041971	c.T302G	p.L101R	rs201665195	0.001506-0.001479	0.0006849	G	deleterious	Possibly damaging	0/1/331	0/2/674	1	1.018
ABCA7	19:1044708	c.G1180C	p.G394R		0-0.0007396	0.000009175	C			0/0/332	0/1/675	1	0
ABCA7	19:1046944	c.C1766G	p.A589G	rs144979723	0-0.0007396	0.0007465	G	Tolerated	Possibly damaging	0/0/332	0/1/675	1	0
ABCA7	19:1047169	c.T1859C	p.L620P	rs144852598	0-0.001479	0.0003622	C	deleterious	probably damaging	0/0/331	0/2/674	1	0
ABCA7	19:1047336	c.G2026A	p.A676T	rs59851484	0-0.0007396	0.01294	A	deleterious	probably damaging	0/0/332	0/1/675	1	0
ABCA7	19:1049312	c.C2428G	p.R810G		0-0.0007396	0.000008437	G			0/0/332	0/1/675	1	0
ABCA7	19:1049318	c.C2434A	p.L812M	NOVEL	0-0.0007396		A			0/0/332	0/1/675	1	0
ABCA7	19:1056126	c.C4300T	p.R1434C	rs137888610	0-0.0007396	0.0001541	T	Tolerated	Possibly damaging	0/0/332	0/1/675	1	0
ABCA7	19:1057056	c.C4737G	p.Y1579X		0-0.0007396	0.0000252	G			0/0/332	0/1/675	1	0
ABCA7	19:1058635	c.C5168T	p.S1723L	rs73505232	0-0.0007396	0.01161	T	deleterious	probably damaging	0/0/332	0/1/675	1	0
ABCA7	19:1059029	c.G5408A	p.R1803H	rs143615723	0-0.0007396	0.000168	A	Tolerated	benign	0/0/332	0/1/675	1	0

ABCA7	19:1063574	c.T5744C	p.L1915P	NOVEL	0-0.0007407		C			0/0/332	0/1/674	1	0
ABCA7	19:1063651	c.G5821A	p.V1941I	rs151130083	0-0.0007396	0.0004578	A	Tolerated	benign	0/0/332	0/1/675	1	0
ABCA7	19:1056492	c.G4580C	p.G1527A	rs3752246	0.1767-0.1629	0.159	C	Tolerated	benign	13/91/227	13/193/466	0.8276	1.036
ABCA7	19:1063831	c.G5920T	p.E1974X	NOVEL	0-0.0007396		T			0/0/332	0/1/675	1	0
ABCA7	19:1042809	c.A563G	p.E188G	rs3764645	0.4517-0.4697	0.4838	G	Tolerated	benign	67/165/99	154/327/195	0.768	0.9500902
ABCA7	19:1065018	c.G6133T	p.A2045S	rs4147934	0.4613-0.4163	0.268	T	Tolerated	benign	114/70/139	179/179/287	0.6808	1.061
ABCA7	19:1055191	c.G4046A	p.R1349Q	rs3745842	0.2987-0.385	0.4433	A			38/111/164	119/261/268	0.001448	0.641
BIN1	2:127811524	c.C1196T	p.P399L	NOVEL	0.001506-0		T			0/1/331	0/0/676	0.3294	Inf
BIN1	2:127806110	c.G1774T	p.V592F	rs199908147	0-0.001479	0.0000165	T	deleterious	probably damaging	0/0/332	0/2/674	1	0
BIN1	2:127808064	c.C1607A	p.T536K		0-0.0007396	0.0000165	T			0/0/332	0/1/675	1	0
BIN1	2:127808076	c.C1595T	p.T532M	rs112318500	0-0.0007396	0.009155	A	deleterious	Possibly damaging	0/0/332	0/1/675	1	0
BIN1	2:127808458	c.T1492C	p.F498L	rs368238742	0-0.0007396	0.00003322	C	tolerated	benign	0/0/332	0/1/675	1	0
BIN1	2:127825804	c.C547T	p.P183S	NOVEL	0-0.0007396		T			0/0/332	0/1/675	1	0
BIN1	2:127808046	c.A1625G	p.K542R	rs138047593	0.00753-0.01109	0.01122	G	deleterious	probably damaging	0/5/327	1/13/662	0.6291	0.7232396
BIN1	2:127834212	c.A155G	p.N52S		0.001506-0	0.000008237	G			0/1/331	0/0/676	0.3294	Inf
CD2AP	6:47573971	c.G1488A	p.M496I	rs143297472	0.003012-0.0007396		A	tolerated	benign	0/2/330	0/1/675	0.2538	4.084666
CD2AP	6:47567069	c.A1307G	p.K436R	NOVEL	0.001506-0		G			0/1/331	0/0/676	0.3294	Inf
CD2AP	6:47563608	c.A1120G	p.T374A	rs138727736	0.00753-0.006657		G	Tolerated	benign	0/5/327	0/9/667	0.782	1.13
CD2AP	6:47512351	c.A329C	p.K110T	NOVEL	0-0.0007396		C			0/0/332	0/1/675	1	0
CD2AP	6:47541940	c.C682T	p.R228W	rs150851309	0-0.0007396	0	T	deleterious	probably damaging	0/0/332	0/1/675	1	0
CD2AP	6:47544775	c.A839G	p.Y280C	NOVEL	0-0.0007396		G			0/0/332	0/1/675	1	0
CD2AP	6:47547209	c.T992A	p.L331H	rs140188898	0-0.0007396	0	A	tolerated	benign	0/0/332	0/1/675	1	0
CD2AP	6:47548605	c.A1014G	p.P338P	NOVEL	0-0.0007396		G			0/0/332	0/1/675	1	0
CD33	19:51728635	c.A199G	p.I67V		0.001506-0	0.00004119	G			0/1/331	0/0/676	0.3294	Inf
CD33	19:51728629	c.G193C	p.A65P	rs115684563	0-0.001479	0.003262	C	tolerated	benign	0/0/332	0/2/674	1	0
CD33	19:51728729	c.G293A	p.R98K	rs148118239	0-0.0007396	0.001	A	tolerated	benign	0/0/332	0/1/675	1	0
CD33	19:51729594	c.T727C	p.F243L	rs11882250	0-0.0007396	0.01017	C	tolerated	benign	0/0/332	0/1/675	1	0
CD33	19:51738465	c.G799A	p.V267I	rs58981829	0-0.0007396	0.01103	A	tolerated	benign	0/0/332	0/1/675	1	0
CD33	19:51738920	c.T913C	p.S305P	rs61736475	0.01355-0.01479	0.04688	C	tolerated	benign	0/9/323	0/20/656	1	0.9140149
CD33	19:51728815	c.T379C	p.Y127H	rs146181856	0.001506-0.003704		C	tolerated	benign	0/1/331	0/5/670	0.6699	0.4
CD33	19:51738917	c.G910A	p.G304R	rs35112940	0.2009-0.2151	0.1603		tolerated	benign	10/113/208	27/236/411	0.5816	0.924
CD33	19:51728477	c.C41T	p.A14V	rs12459419	0.3106-0.3207	0.2939	T	deleterious	benign	29/147/154	75/281/316	0.946	1.014
CD33	19:51728641	c.A205G	p.R69G	rs2455069	0.4258-0.4302	0.3577		tolerated	benign	60/161/109	131/317/225	0.9432	1.018
CLU	8:27461872	c.C870G	p.H290Q	NOVEL	0-0.0007396		G			0/0/332	0/1/675	1	0
CLU	8:27466474	c.A227C	p.E76A	rs372043736	0-0.0007396	0.00001647	C	deleterious	benign	0/0/332	0/1/675	1	0
CLU	8:27457512	c.A949C	p.N317H	rs9331936	0.001506-0	0.01922	C	deleterious	probably damaging	0/1/331	0/0/676	0.3294	Inf
CLU	8:27462725	c.G545A	p.R182H	rs201670453	0.001506-0	0.000511	A	tolerated	benign	0/1/331	0/0/676	0.3294	Inf
CLU	8:27462744	c.A526G	p.M176V	NOVEL	0.001506-0		G			0/1/331	0/0/676	0.3294	Inf

CLU	8:27462662	c.C608T	p.T203I	rs41276297	0.001506-0.003698	0.001673	T	tolerated	benign	0/1/331	0/5/671	0.6699	0.4
CR1	1:207741336	c.C2770G	p.P924A		0.001506-0	0.00007469	G			0/1/331	0/0/676	0.3294	Inf
CR1	1:207782916	c.A4828T	p.T1610S	rs4844609	0.03313-0.02515	0.0147	T	Tolerated	benign	1/20/311	0/34/642	0.4607	1.27
CR1	1:207679348	c.G221A	p.R74H	rs200913967	0.001506-0.002219	0.0008698	A	tolerated	benign	0/1/331	0/3/673	1	0.677986
CR1	1:207680071	c.G314A	p.R105H	rs56102840	0-0.0007396	0.00004973	A	tolerated	benign	0/0/332	0/1/675	1	0
CR1	1:207680127	c.G370A	p.G124R		0-0.0007396	0.00005806	A			0/0/332	0/1/675	1	0
CR1	1:207680154	c.A397G	p.K133E	rs183171969	0-0.0007396	0.0002253	G	tolerated	benign	0/0/332	0/1/675	1	0
CR1	1:207739203	c.C2537T	p.S846F	rs199990810	0-0.0007396	0.000365	T	tolerated	Possibly damaging	0/0/332	0/1/675	1	0
CR1	1:207741193	c.T2627C	p.V876A	rs149099494	0-0.0007396	0.00595	C	tolerated	benign	0/0/332	0/1/675	1	0
CR1	1:207751179	c.G3217A	p.A1073T	rs187750583	0-0.0007396	0.0004809	A	tolerated	Possibly damaging	0/0/332	0/1/675	1	0
CR1	1:207751252	c.T3290C	p.L1097P	rs200111726	0-0.0007407	0.003333	C	tolerated	Possibly damaging	0/0/332	0/1/674	1	0
CR1	1:207751260	c.A3298G	p.R1100G	rs202070239	0-0.0007407	0.003284	G	tolerated	benign	0/0/332	0/1/674	1	0
CR1	1:207760830	c.G4280A	p.R1427H	rs373049995	0-0.0007396	0.0001491	A	tolerated	benign	0/0/332	0/1/675	1	0
CR1	1:207760852	c.G4302A	p.M1434I	rs140566582	0-0.001479	0.0006462	A	tolerated	benign	0/0/332	0/2/674	1	0
CR1	1:207785022	c.T4946C	p.V1649A		0-0.0007396	0.00004155	C			0/0/332	0/1/675	1	0
CR1	1:207785099	c.G5023T	p.V1675L	rs202148801	0.003012-0.003698	0.001747	T	tolerated	benign	0/2/330	0/5/671	1	0.81
CR1	1:207787763	c.G5240A	p.G1747D	rs200692346	0-0.0007396	0.0007873	A	deleterious	benign	0/0/332	0/1/675	1	0
CR1	1:207790017	c.C5409G	p.C1803W		0-0.0007396	0.00003312	G			0/0/332	0/1/675	1	0
CR1	1:207790110	c.C5502A	p.S1834R	NOVEL	0-0.0007396		A			0/0/332	0/1/675	1	0
CR1	1:207782856	c.A4768G	p.K1590E	rs17047660	0-0.002219	0.02141	G	tolerated	possibly damaging	0/0/332	0/3/673	0.5549	0
CR1	1:207782769	c.G4681A	p.V1561M	rs41274768	0.0256-0.02959	0.02487	A	tolerated	possibly damaging	0/17/315	1/38/637	0.7704	0.88
CR1	1:207791434	c.A5558G	p.K1853R	rs41274770	0.03464-0.02441	0.0153	G	tolerated	benign	0/23/309	1/31/644	0.1834	1.49
CR1	1:207680157	c.G400A	p.G134R		0.003012-0.0007396	0.00008366	A			0/2/330	0/1/675	0.2538	4.084
CR1	1:207680070	c.C313T	p.R105C	rs11587944	0.009036-0.01479	0.007601	T	tolerated	possibly damaging	0/6/326	1/18/657	0.3951	0.636
CR1	1:207782889	c.A4801G	p.R1601G	rs17047661	0.001506-0.004438	0.05483	G	tolerated	benign	0/1/331	0/6/670	0.4363	0.33
CR1	1:207760772	c.A4222G	p.T1408A	rs61734514	0.03464-0.03107	0.01843	G	tolerated	benign	1/21/310	1/40/635	0.7821	1.099
CR1	1:207782707	c.A4619G	p.N1540S	rs17259045	0.1099-0.1095	0.08897	G	tolerated	benign	4/65/263	8/132/536	1	1
CR1	1:207795320	c.A5905G	p.T1969A	rs2296160	0.2078-0.1711	0.1841	G	tolerated	benign	22/94/216	17/197/461	0.3178	1.15
CR1	1:207782931	c.A4843G	p.I1615V	rs6691117	0.2274-0.2101	0.3341	G	Tolerated	benign	17/117/198	33/218/425	0.3346	1.14
CR1	1:207760773	c.C4223T	p.T1408M	rs3737002	0.2831-0.2911	0.275	T	tolerated	possibly damaging	26/136/170	54/285/336	0.6878	0.944
CR1	1:207790088	c.C5480G	p.P1827R	rs3811381	0.1955-0.1748	0.2403	G			13/103/214	24/188/463	0.2519	1.18
CR1	1:207753621	c.A3623G	p.H1208R	rs2274567	0.1973-0.1778	0.251	G	tolerated	Possibly damaging	13/105/214	26/187/459	0.2259	1.188014
EPHA1	7:143095907	c.G1123A	p.G375S	rs149370167	0.001506-0	0.0001187	A	Tolerated	benign	0/1/331	0/0/676	0.3294	Inf
EPHA1	7:143092269	c.C2090T	p.P697L	rs34372369	0.04669-0.04882	0.04929	T	Tolerated	Possibly damaging	2/27/303	3/60/613	0.8166	0.931

EPHA1	7:143088576	c.T2905C	p.C969R	rs61732993	0.001506-0.002219	0.0003652	C	Tolerated	Possibly damaging	0/1/331	0/3/673	1	0.677
EPHA1	7:143088779	c.G2786A	p.R929H	rs201365734	0-0.0007396	0.0002313	A	Tolerated	Possibly damaging	0/0/332	0/1/675	1	0
EPHA1	7:143095849	c.C1181T	p.P394L	rs140236236	0-0.0007396	0.0003166	T			0/0/332	0/1/675	1	0
EPHA1	7:143095979	c.C1051T	p.R351C	rs56006153	0-0.0007396	0.0001114	T	deleterious	benign	0/0/332	0/1/675	1	0
EPHA1	7:143096369	c.C973T	p.P325S	NOVEL	0-0.0007396		T			0/0/332	0/1/675	1	0
EPHA1	7:143096809	c.T770G	p.V257G	rs201380861	0-0.0007418		G	deleterious	Possibly damaging	0/0/329	0/1/673	1	0
EPHA1	7:143098598	c.A251G	p.N84S	rs142191815	0-0.0007396	0.0002481	G	Tolerated	benign	0/0/332	0/1/675	1	0
EPHA1	7:143098605	c.C244T	p.R82C	rs74721927	0-0.0007396	0.00002481	T	deleterious	Possibly damaging	0/0/332	0/1/675	1	0
EPHA1	7:143105828	c.G71A	p.R24H	rs79587607	0.003012-0.003704		A	Tolerated	benign	0/2/330	1/3/671	1	1.016659
EPHA1	7:143088584	c.G2897A	p.R966H	rs139482378	0.001506-0.0007396	0.0006136	A	deleterious	probably damaging	0/1/331	0/1/675	0.5505	2.037766
EPHA1	7:143095153	c.G1475A	p.R492Q	rs11768549	0.0256-0.01479	0.0121	A	tolerated	benign	0/17/315	1/18/657	0.07162	1.864999
EPHA1	7:143096020	c.G1010A	p.R337Q	rs201581948	0.001506-0	0.000357	A	tolerated	benign	0/1/331	0/0/676	0.3294	Inf
EPHA1	7:143088867	c.A2698G	p.M900V	rs6967117	0.06949-0.0638	0.0634		tolerated	benign	4/38/289	3/80/591	0.9191	1.031239
EPHA1	7:143097100	c.T479C	p.V160A	rs149370167	0.07553-0.06899					3/44/284	2/89/583	0.7704	1.06
MS4A6A	11:59949058	c.T143C	p.I48T	rs61742546	0.02711-0.02885	0.01537	C	deleterious	Possibly damaging	0/18/314	0/39/637	0.8854	0.936
MS4A6A	11:59940599	c.A553T	p.T185S	rs7232	0.3313-0.3741	0.3131	A	deleterious	benign	36/148/148	103/299/273	0.2216	0.844
MS4A6A	11:59940532	c.G620A	p.R207Q	rs146398167	0.001506-0	0.00004118	A	tolerated	benign	0/1/331	0/0/676	0.3294	Inf
PICALM	11:85685839	c.G1835T	p.S612I		0-0.0007396	0.00004119	T			0/0/332	0/1/675	1	0
PICALM	11:85687719	c.C1765G	p.P589A	rs147556602	0-0.0007396	0.0002729	G	tolerated	benign	0/0/332	0/1/675	1	0
PICALM	11:85707896	c.G1231C	p.A411P	rs34013602	0.001506-0.002219	0.001533	C	tolerated	benign	0/1/331	0/3/673	1	0.6779869
PICALM	11:85707933	c.G1194T	p.Q398H		0.001506-0	0.000008246	T			0/1/331	0/0/676	0.3294	Inf
PICALM	11:85701307	c.A1373G	p.H458R	rs117411388	0.001506-0.0007396	0.0007449	G	tolerated	benign	0/1/331	0/1/675	0.5505	2.037
PICALM	11:85779721	c.C102G	p.I34M	rs146840505	0.00303-0.002219	0.001638	G	tolerated	benign	0/2/328	0/3/673	0.6652	1.36

Table S1. Common, low frequency and rare variants detected in our cohort. Position is in Hg19. MAF, minor allele frequency; OR, odds ratio; Inf, infinity. Highlighted in grey and blue, singletons and common coding variants, respectively. These variants have been excluded from the study. If we would have included also the common coding variants (16 variants) in the single-variants based analysis, the p-value for the statistical significance would have been $p < 3.9 \times 10^{-4}$ (0.05/128 coding variants).

GENE	RELATIVE FREQUENCY OF LOW FREQUENCY AND RARE CODING VARIANTS
<i>PICALM</i>	3.27
<i>CR1</i>	4.08
<i>CD2AP</i>	4.16
<i>MS4A6A</i>	4.42
<i>CLU</i>	4.44
<i>EPHA1</i>	5.11
<i>ABCA7</i>	5.58
<i>BIN1</i>	6.17
<i>CD33</i>	7.5

Table S2. Relative frequency of low frequency and rare coding variants in our cohort.

GENE	POSITION	RS ID	Cdna	Aa change	MA	CARRIER. AD (%)	CARRIER. CTRLS (%)	MAF cases-ctrls (%)	PVAL	OR
<i>ABCA7</i>	19:1047002	rs3752234	c.A1824G	p.A608A	G	152/315 (48.25)	402/666 (60.36)	33.17-41.29	0.0004289	0.612
<i>ABCA7</i>	19:1043103	rs72973581	c.G643A	p.G215S	A	55/639 (8.6)	165/1177(14)	4.3-7	0.0006	0.57
<i>ABCA7</i>	19:1055191	rs3745842	c.G4046A	p.R1349Q	A	149/313 (47.6)	380/648 (58.64)	29.87-38.5	0.001448	0.641
<i>ABCA7</i>	19:1061804	rs78320196	c.T5487C	p.N1829N	C	17/332 (5.12)	66/674 (9.8)	2.5-4.97	0.01049	0.497
<i>ABCA7</i>	19:1053524	rs3752241	c.C3417G	p.L1139L	G	76/329 (23.1)	204/671 (30.4)	12.31-16.09	0.01647	0.687
<i>ABCA7</i>	19:1041347	rs182233998	c-14T>C	5 prime UTR variant	C	5/332 (1.5)	30/676 (4.43)	0.7-2.21	0.01667	0.3295442
<i>ABCA7</i>	19:1065044	rs4147935	c.C6159T	p.G2053G	T	132/325 (40.61)	316/665 (47.51)	24.39-26.62	0.04164	0.755

Table S3. Main coding and non-coding variants detected in *ABCA7* in our cohort. Position is in Hg19. All these variants except *ABCA7* rs72973581 have been excluded from our study either because they were common coding or non coding variants. If these would have been included, they would have been nominally significant after the multiple testing correction.

Position	MA	RS ID	Aa change	aa/Aa/AA cases	aa/Aa/AA controls	ExAC MAF	P-Value	OR
19:1047002	G	rs3752234	p.A608A	57/95/163	148/254/264	0.5547	0.0004289	0.612
19:1055191	A	rs3745842	p.R1349Q	38/111/164	119/261/268	0.4433	0.001448	0.641
19:1061804	C	rs78320196	p.N1829N	0/17/315	1/65/608	0.05847	0.01049	0.497
19:1053524	G	rs3752241	p.L1139L	5/71/253	12/192/467	0.2525	0.01647	0.687
19:1041347	C	rs182233998	splice region	0/5/327	0/30/646	0.01511	0.0166	0.329
19:1043103	A	rs72973581	p.G215S	0/31/301	1/96/579	0.04316	0.02665	0.615
19:1065044	T	rs4147935	p.G2053G	30/102/193	72/244/349	0.4049	0.04164	0.755
19:1050996	A	rs74176364	p.A877T	0/2/330	0/16/660	0.01692	0.07264	0.25
19:1059056	A	rs114782266	p.R1812H	0/10/322	0/11/665	0.01057	0.1625	1.87
19:1064193	G	rs4147930	p.L1995L	19/115/191	34/275/363	0.7303	0.1739	0.824
19:1041352	G	rs3752229	splice acceptor	2/36/294	1/59/616	0.06973	0.2136	1.326
19:1057343	A	rs117187003	p.V1599M	0/4/328	0/3/673	0.003085	0.2269	2.73
19:1041909	T	rs144546979	p.T80T	0/2/330	0/1/675	0.000144	0.2538	4.08
19:1052086	A	rs61576791	p.T1036T	0/2/330	0/1/675	0.01736	0.2538	4.084
19:1065563	G	rs2242437	3'UTR	18/119/190	36/270/363	0.395	0.2774	0.855
19:1047537	C	rs3752239	p.N718T	0/11/321	0/33/641	0.07028	0.3251	0.665
19:1043794	A	rs147846250	p.R334Q	0/1/331	0/0/676	0.0002	0.329	Inf
19:1044619	G	rs146982710	p.P364R	0/1/331	0/0/676	0.000384	0.329	Inf
19:1046239	G	rs141428162	p.P486A	0/1/331	0/0/676	0.000321	0.3294	Inf
19:1047372	A	NOVEL	p.A688T	0/1/331	0/0/676	NA	0.3294	Inf
19:1053521	G	NOVEL	p.S1138R	0/1/331	0/0/676	2.87E-05	0.3294	Inf
19:1056372	G	NA	p.V1487G	0/1/331	0/0/676	0.000125	0.3294	inf
19:1056941	A	rs145632609	p.C1541Y	0/1/331	0/0/676	4.13E-05	0.3294	Inf
19:1056958	C	NA	p.S1547P	0/1/331	0/0/676	8.26E-06	0.3294	Inf
19:1057366	T	NOVEL	p.Q1606H	0/1/331	0/0/676	NA	0.3294	Inf
19:1058655	A	NOVEL	p.V1730I	0/1/331	0/0/676	NA	0.3294	inf
19:1044712	G	rs3764647	p.H395R	0/17/315	0/45/630	0.06298	0.4032	0.755
19:1043748	G	rs3752232	p.T319A	0/17/315	0/44/630	0.06039	0.4035	0.77

19:1058176	G	rs4147918	p.Q1686R	0/17/315	0/43/633	0.04785	0.4812	0.794
19:1049269	A	rs4147914	p.L795L	6/65/255	12/147/511	0.1781	0.5221	0.894
19:1056109	T	rs145232000	p.S1428L	0/1/331	0/1/675	0.000199	0.5505	2.037
19:1056918	T	NA	p.S1533S	0/1/331	0/1/675	0.000925	0.5505	2.037
19:1053382	G	NA	p.V1092G	1/0/329	0/1/670	0.000806	0.5509	2.034
19:1062192	C	rs4147921	A1864A	0/16/315	0/40/635	0.04819	0.5592	0.8
19:1043747	T	rs149023827	p.L318L	0/3/329	0/10/665	0.001779	0.5623	0.6
19:1065018	T	rs4147934	p.A2045S	114/70/139	179/179/287	0.7317	0.6808	1.061
19:1041852	T	rs3764644	p.L61L	0/16/315	0/36/631	0.05701	0.7641	0.89
19:1042809	G	rs3764645	p.E188G	67/165/99	154/327/195	0.4838	0.768	0.9500902
19:1051214	G	rs3752240	p.V915V	42/157/132	86/313/275	0.3361	0.785	1.039
19:1056492	G	rs3752246	p.G1527A	13/91/227	13/193/466	0.8405	0.8276	1.036
19:1052005	T	rs3764652	p.A1009A	61/162/104	130/330/210	0.4256	0.8848	0.978
19:1041289	T	NOVEL	c.231-12C>A	0/0/332	0/1/675	NA	1	0
19:1041922	A	NOVEL	p.L85M	0/0/332	0/1/675	0.000257	1	0
19:1041950	C	NOVEL	p.L94P	0/0/332	0/1/675	NA	1	0
19:1041951	A	NOVEL	p.L94L	0/0/332	0/1/675	NA	1	0
19:1041971	G	NA	p.L101R	0/1/331	0/2/674	0.000685	1	1.018
19:1043350	T	NA	p.L270L	0/0/332	0/1/675	0.000906	1	0
19:1044692	T	NA	p.D388D	0/0/332	0/1/675	5.28E-05	1	0
19:1044708	C	NA	p.G394R	0/0/332	0/1/675	9.18E-06	1	0
19:1046944	G	rs144979723	p.A589G	0/0/332	0/1/675	0.000747	1	0
19:1047169	C	rs144852598	p.L620P	0/0/331	0/2/674	0.000362	1	0
19:1047336	A	rs59851484	p.A676T	0/0/332	0/1/675	0.01294	1	0
19:1048982	T	rs9282560	p.C786C	0/1/331	0/2/674	0.001928	1	1.018
19:1049305	A	rs4147915	p.V807V	3/74/248	24/133/508	0.1792	1	1
19:1049312	G	NA	p.R810C	0/0/332	0/1/675	8.44E-06	1	0
19:1049318	A	NOVEL	p.L812M	0/0/332	0/1/675	NA	1	0
19:1051944	A	rs139214131	p.R989H	0/0/332	0/2/674	0.00068	1	0
19:1052017	A	NOVEL	p.G1013G	0/0/332	0/1/675	0.000204	1	0
19:1054060	G	rs3752243	p.L1176L	54/173/105	127/334/212	0.4723	1	0.99

19:1054791	G	NOVEL	p.P1288P	0/0/332	0/1/675	NA	1	0
19:1055249	A	NA	p.P1368P	0/0/332	0/1/675	8.79E-05	1	0
19:1056065	G	rs881768	p.R1413R	54/161/107	128/317/221	0.4451	1	0.99
19:1056110	A	NA	p.S1428S	0/0/332	0/1/675	0.000121	1	0
19:1056126	T	rs137888610	p.R1434C	0/0/332	0/1/675	0.000154	1	0
19:1056421	A	rs113711363	p.P1503P	0/0/332	0/1/675	0.00593	1	0
19:1057047	A	NA	p.P1576P	0/0/332	0/1/675	3.34E-05	1	0
19:1057056	G	rs148266574	p.Y1579X	0/0/332	0/1/675	2.52E-05	1	0
19:1058635	T	rs73505232	p.S1723L	0/0/332	0/1/675	0.01161	1	0
19:1059029	A	rs143615723	p.R1803H	0/0/332	0/1/675	0.000168	1	0
19:1063574	C	NOVEL	p.L1915P	0/0/332	0/1/674	NA	1	0
19:1063651	A	rs151130083	p.V1941I	0/0/332	0/1/675	0.000458	1	0
19:1063831	T	NOVEL	p.E1974X	0/0/332	0/1/675	NA	1	0

Table S4. Collection of all the variants included in the *ABCA7* gene-based analysis. Position is in Hg19. MAF, minor allele frequency; OR, odds ratio; Inf, infinity

GENE	TRANSCRIPT	POSITION	MA	Aa change	rs	ExAC MAF(%)	POLYPHEN	GERP* score	Grantham** score	P-value	OR (95% CI)	Disease	Ref.
<i>IL23R</i>	NM_144701.2	1:67635211	G>A	p.R86Q	rs76575803	0.2776	benign	-2.52	43	0.010	0.40 (0.000-1.031)	CD	(1)
<i>IL23R</i>	NM_144701.2	1:67648596	G>A	p.G149R	rs76418789	0.7084	probably-damaging	5.24	125	1.46x10 ⁻³	0.335 (0.000-0.843)	CD, UL	(1)(2)
<i>IL23R</i>	NM_144701.2	1:67705900	G>A	p.V362I	rs41313262	1.168	benign	-6.22	29	2.89x10 ⁻⁴	0.567 (0.000-0.821)	CD, UL	(1)(2)
<i>IL23R</i>	NM_144701.2	1:67705958	G>A	p.R381Q	rs11209026	4.221	probably-damaging	5.19	43	<1.00x10 ⁻⁶	0.363 (0.000-0.452)	CD, UL	(1)
<i>IFIH1</i>	NM_022168.3	2:163124637	T>C	I923V	rs35667974	1.156	probably-damaging	5.13	29	2.1x10 ⁻¹⁶	0.51 (0.43 - 0.61)	T1D	(3)
<i>IFIH1</i>	NM_022168.3	2:163134090	C>A	E627X	rs35744605	0.0008288	NA	2.87	NA	1.3x10 ⁻³	0.69 (0.52 - 0.91)	T1D	(3)
<i>G6PC2</i>	NM_021176.2	2:169764176	G>C	p.V219L	rs492594	48.65	benign	3.06	32	NA	NA	T2D	(4)
<i>TMEM106B</i>	NM_001134232.1	7:12269417	C>G	p.T185S	rs3173615	46.16	benign	5.36	58	NA	NA	FTLD	(5)
<i>ABCA7</i>	NM_019112	19:1043103	G>A	p.G215S	rs72973581	4.31	benign	-5.86	56	6x10 ⁻⁴	0.57 (0.41-0.80)		

Table S5. Protective variants reported at the GWAS loci. Position is in Hg19. MAF, minor allele frequency; Aa, amino acid; OR, odds ratio; Ref., reference; CD, Chron's disease; UL, ulcerative colitis; FTLN, frontotemporal lobar degeneration. .

*GERP score >5 indicates high conservation among different species

**Grantham score < 50 indicates an amino acid substitution that does not importantly alter the protein sequence

GENE	TRANSCRIPT	POSITION	MA	Aa change	rs ID	ExAC MAF(%)	POLYPHEN	GERP* score	Grantham** score	P-value	OR	EFFECT	Ref.
ABCA1	NM_005502.3	9:107599376	A>G	V399A	rs9282543	0.3520	benign	5.7	64	0.6273	0.38	Potential protective factor for AD	(6)
ABCA1	NM_005502.3	9:107589255	C>T	V771M	rs2066718	5.11	benign	4.55	21	0.1495	0.43	Potential protective factor for AD	(6)
ABCA1	NM_005502.3	9:104819652	G>A	P1059S	rs371168450	NA	Probably damaging	NA	NA	0.04705	0.49	Potential protective factor for AD	(6)
ABCA1	NM_005502.3	9:107579632	C>G	E1172D	rs33918808	3.82	benign	4.68	45	1	0.96	Potential protective factor for AD	(6)

Table S6. Potential protective variants for AD reported in ABCA1 (6). MAF, minor allele frequency; Aa, amino acid; OR, odds ratio; Ref., reference; AD, Alzheimer’s disease.

*GERP score >5 indicates high conservation among different species

**Grantham score < 50 indicates an amino acid substitution that does not importantly alter the protein sequence




Figure S1. Pipeline of our study design. WES, whole exome sequencing; WGS, whole genome sequencing; INDELS, in frame insertions and deletions; SNVs, single nucleotide variants; CTRLS, controls; UTRs, untranslated regions. * INDELS have been excluded from the discovery cohort because not targeted in the BYU dataset.

<i>Homo Sapiens</i>	197	L-R-S-L-V-E-L-R-A-L-L-Q-R-P-R-G-T-S- G -P-L-E-L-L-S-E-A-L-C-S-V-R-G-P-S-S-T
<i>Gorilla</i>	197	L-R-S-L-V-E-L-Q-A-L-L-R-R-P-R-G-T-S- G -P-L-E-L-L-S-E-A-L-C-S-A-R-G-P-S-S-T
<i>Macaca mulatta</i>	195	L-P-S-L-G-E-L-W-A-L-L-Q-R-P-H-R-P-G- G -P-L-E-A-V-A-E-A-L-C-S-A-R-G-P-S-K-P
<i>Bos Taurus</i>	197	L-P-S-L-V-E-L-Q-A-L-L-H-R-P-R-G-T-G- G -P-L-E-L-L-S-E-A-L-C-S-A-R-G-P-S-S-T
<i>Rattus norvegicus</i>	193	L-P-S-L-V-E-L-R-A-L-L-R-R-P-Q-G-P-G- G -P-L-E-A-V-S-E-A-L-C-G-A-R-G-P-G-I-P
<i>Mus musculus</i>	194	L-P-S-L-M-E-L-R-A-L-L-R-R-P-R-G-S-A- G -S-L-E-L-V-S-E-A-L-C-S-T-K-G-P-S-S-P
<i>Canis lupus</i>	194	L-P-S-L-V-E-L-R-A-L-L-R-R-P-Q-G-T-R- S -P-L-Q-L-V-S-E-A-F-C-S-A-K-G-P-S-S-P
<i>Pteropus vampyrus</i>	191	L-P-S-L-A-E-L-Q-A-L-L-P-R-L-R-E-T-D- S -T-L-A-V-V-S-E-A-L-C-S-A-K-G-P-S-V-P-G-G-P-S
<i>Cavia porcellus</i>	272	L-P-S-L-A-E-L-Q-A-L-L-Q-R-P-W-G-T-S- S -S-L-E-L-V-S-E-A-L-C-S-A-K-G-P-S-S-P-G-G

Figure S2. Conservation of ABCA7 p.G215 in different species

ABCA7	197	L-R-S-L-V-E-L-R-A-L-L-Q-R-P-R-G-T-S- G -P-L-E-L-L-S-E-A-L-C-S-V-R-G-P-S-S-T
ABCA2	241	T-P-G-S-G-E-L-G-R-I-L-T-V-P-E-S-Q-K- G -A-L-Q-G-Y-R-D-A-V-C-S-G-Q-A
ABCA12	701	R-S-V-P-L-T-Q-A-M-Y-R-S-N-R-M-N-T-P-Q- G -S-F-S-T-I-S-Q-A-L-C
ABCA13	3217	L-L-E-T-L-D-F-Q-Q-V-S-Q-N-V-Q-A-R-S-S-A-F- G -S-F-Q-F-V-M-K-M-V-C—K-D-Q-A-S-F
ABCA1	274	M-R-S-W-S-D-M-R-Q-E-V-M-F-L-T-N-V-N-S- S -S-S-S-T-Q-I-Y-Q-A-V-S-R

Figure S3. Conservation of ABCA7 p.G215 in homologous protein

Bioinformatic

Each of the samples in our dataset consisted of paired-end 100 base pair reads. We used the Burrows-Wheeler Aligner (BWA)(7) to map the reads to build of the human genome (hg19/GRCh37). Following read mapping, we used SAMtools (8), Picard (<http://picard.sourceforge.net>), and the Genome Analysis Toolkit (GATK) (9)(10) to refine the resulting alignments by removing duplicates, performing realignment around InDels, and recalibrating base quality scores. We then used the GATK's UnifiedGenotyper to identify sequence variants, and subsequently filtered the variants and recalibrated variant quality scores (9). Our final dataset consisted of variant call format (VCF) files containing variants that passed all filters. Since our dataset consisted of a mix of exomes captured using different kits, and whole genome sequences, we employed a highly conservative approach to variant selection to increase our confidence that analyzed variants are true positives. We limited our dataset of variants to only those genomic regions we expected to have been sequenced in each of the exomes (based on capture probes used for exome library preparation) and whole genomes. Next, we compiled a list of all the variants present in at least a single sample. We examined each of the variants from the list of total variants in each sample, whether or not the variant was called by the GATK, and reassigned the genotype for that variant according to the following criteria. (1) If the variant was called by the GATK and passed all filters, we used the GATK genotype. (2) If no variant was called at the genomic position in question, we returned to the raw VCF file and if there were reads containing the variant, but the variant was not called because of failing filters or because only a small number of reads contain the variant, we set the genotype to missing for the sample. (3) Finally, if all the reads at this position for the sample indicated reference alleles, we set the genotype to homozygous reference. Resulting sequence files were converted to Plink format (11) using VCFTools (12). Lastly, we removed all variants not in our pre-defined list of candidate genes (*ABCA7* [NM_019112]; *CD2AP* [NM_012120]; *MS4A6A* [NM_152851]; *CR1* [NM_000573]; *BIN1* [NM_139343]; *PICALM* [NM_001206946]; *EPHA1* [NM_005232]; *CLU* [NM_001831]; *CD33* [NM_001772]). Remaining variants were annotated using ANNOVAR (13). Each variant was annotated with gene information (gene name, transcript ID, and transcript and protein positions of the variant), genomic location (exon, intron, UTR, intergenic, etc.), one or more variant classes (5'-UTR, 3'-UTR, intergenic, intronic, splice site, nonsynonymous, stop-gain, stop-loss, or synonymous), the 1000 Genomes minor allele frequency (14), dbSNP

identifier(15), and PolyPhen-2 (16).

References

1. Momozawa Y, Mni M, Nakamura K, Coppieters W, Almer S, Amininejad L, et al. Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. *Nat Genet.* 2011 Jan;43(1):43–7.
2. Rivas MA, Beaudoin M, Gardet A, Stevens C, Sharma Y, Zhang CK, et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. *Nat Genet.* 2011 Nov;43(11):1066–73.
3. Nejentsev S, Walker N, Riches D, Egholm M, Todd JA. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. *Science.* 2009 Apr 17;324(5925):387–9.
4. Mahajan A, Sim X, Ng HJ, Manning A, Rivas MA, Highland HM, et al. Identification and functional characterization of G6PC2 coding variants influencing glycemic traits define an effector transcript at the G6PC2-ABCB11 locus. *PLoS Genet.* 2015 Jan;11(1):e1004876.
5. Nicholson AM, Finch NA, Wojtas A, Baker MC, Perkerson RB, Castanedes-Casey M, et al. TMEM106B p.T185S regulates TMEM106B protein levels: implications for frontotemporal dementia. *J Neurochem.* 2013 Sep;126(6):781–91.
6. Lupton MK, Proitsi P, Lin K, Hamilton G, Daniilidou M, Tsolaki M, et al. The role of ABCA1 gene sequence variants on risk of Alzheimer’s disease. *J Alzheimers Dis JAD.* 2014;38(4):897–906.
7. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinforma Oxf Engl.* 2009 Jul 15;25(14):1754–60.
8. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. *Bioinforma Oxf Engl.* 2009 Aug 15;25(16):2078–9.
9. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet.* 2011 May;43(5):491–8.
10. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res.* 2010 Sep;20(9):1297–303.
11. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet.* 2007 Sep;81(3):559–75.
12. Danecek P, Auton A, Abecasis G, Albers CA, Banks E, DePristo MA, et al. The variant call format and VCFtools. *Bioinforma Oxf Engl.* 2011 Aug 1;27(15):2156–8.

13. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res.* 2010 Sep;38(16):e164.
14. 1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, et al. An integrated map of genetic variation from 1,092 human genomes. *Nature.* 2012 Nov 1;491(7422):56–65.
15. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. *Nucleic Acids Res.* 2001 Jan 1;29(1):308–11.
16. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. *Nat Methods.* 2010 Apr;7(4):248–9.
17. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc.* 2009;4(7):1073–81.

and SIFT (17) functional predictions.